Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Whether the high incidence of thromboembolic events in nephrotic patients with membranous nephropathy justifies prophylactic administration of oral anticoagulants remains controversial. We used a Markov-based decision analysis model, explicitly considering the consequences of recurrent embolic and bleeding events to quantify the risk-benefit trade-offs of: (1) prophylactic therapy, in which oral anticoagulation was started at the time of diagnosis of nephrotic syndrome (before any thromboembolic event); and (2) anticoagulant therapy, in which treatment was started after the first clinical thromboembolic event. We assumed that anticoagulant therapy was discontinued if there was remission of the nephrotic syndrome. The overall number of fatal emboli prevented by prophylactic anticoagulants exceeded the one of fatal bleeding events for all clinically meaningful ranges of the following parameters: nephrotic syndrome duration, incidence of thromboembolic events, likelihood of embolization, and mortality rates of embolic and bleeding events. For a hypothetical 50-year-old patient who remained nephrotic for 2 years, prophylactic anticoagulation yielded a gain representing 2.5 months of quality-adjusted life expectancy. We conclude that for nephrotic patients with membranous nephropathy, the benefits of prophylactic administration or oral anticoagulants outweigh the risks.
© 1994 by the International Society of Nephrology nephrotic patients with membranous nephropathy, whether prophylactic oral anticoagulant therapy is justified remains unanswered and is controversial in the literature. We have used a Markov-based decision analysis model, explicitly considering the consequences of recurrent embolic and bleeding events, to examine the risks and benefits of oral anticoagulant therapy started immediately after the first clinical thromboembolic episode with a strategy of prophylactic oral anticoagulant therapy.
Methods
Decision analysis is a technique for choosing among alternate strategies [4, 5] . To analyze a decision, the strategies are defined, subsequent important and plausible clinical events for each strategy are described, and the probability of each event is specified. A value (utility) is assigned to each state of health considered, and the expected utility for each strategy is calculated. The strategy with the greatest expected utility is the preferred choice. The structure of the analysis is described below. The Appendix gives detailed explanations about the model itself, the assumptions, the utilities, and the chance events in the decision tree.
The decision model To examine the question of prophylactic oral anticoagulation in nephrotic patients, we developed a model that balances the risks and benefits of long-term oral anticoagulation. The decision tree ( Fig. 1) describes the choices and chances facing the patient and physician. The square node at the left represents the choice between the two strategies: (1) Observation, in which oral anticoagulant therapy is started in patients having suffered and survived a clinically apparent thromboembolic event, and (2) Anticoagulation, in which anticoagulant therapy is started at the time of diagnosis of nephrotic syndrome, before any clinically apparent thromboembolic event (prophylactic therapy). In both strategies, oral anticoagulant therapy is only administered as long as patients remain nephrotic. If remission of the nephrotic syndrome occurs, anticoagulation is discontinued. We used a Markov state transition model represented by the infinity sign to simulate recurrent chance events beyond the patient and physician's control [6] . Recurrent chance events (Fig. 1 , B through D), represented by round nodes include age, sex, race and membranous nephropathy-related mortality, as well as embolic and bleeding events with their consequences and related morbidities. Table I summarizes the rates and probabilities used in the analysis. The range of estimates derived from literature sources, and the baseline values used in our analysis are included. Justifications for some data are given in the accompanying Appendix. Monthly transition probabilities were calculated for the Markov simulation from annual rates using the formula: monthly probability = 1 -e(_hI rate x 1/12 years) Review of relevant data Thromboembolism in nephrotic patients. There has been much controversy about the true incidence of renal vein thrombosis (RVT), and deep vein thrombosis in the legs (DVT) in Probabilities and rates used in the baseline analysis above contention is that thrombosis is much more common in patients with a nephrotic syndrome arising from idiopathic membranous nephropathy (MGN), when compared to the incidence in other varieties of nephrotic syndrome, including membranoprolilerative glomerulonephritis, focal glomerulosclerosis, and rapidly progressive glomerulonephntis (10) (11) (12) . Thromboses also seem to parallel the degree of hypoalbuminemia since thromboembolic events are more frequent in patients with low albumin level (<2 gIdl) [1, 2, 13, 141. Table 2 shows the incidence of both clinically apparent and silent thromboses (RVT and DVT) in two different nephrotic populations: (I) nephrotic patients with membranous nephropathy; and (2) patients with nephrotic syndrome of other types. We used the studies for which time dependent data are available to calculate the monthly incidence of RVT and DVT. In our baseline analysis, we only considered the incidence of clinically apparent thromboses, that is 0.5% per month for RVT and 1% per month for DVT (Table 2) . A critical overview of the literature and justifications for the use of the data employed are given in the Appendix.
Venous thrombosis and pulmonary embolism. In the setting of renal vein thrombosis, the likelihood of embolization is difficult to assess, as many RVT are clinically inapparent.
However, for Cameron, pulmonary embolism occurred in 20% to 40% of untreated RVT (Appendix) [1].
The likelihood of embolization from deep venous thrombi (DVT) is dependent upon anatomical location. Approximately 50% of untreated clinically apparent proximal deep venous thrombi in the legs embolize to the lungs (Appendix) [15, 16] .
Pulmonary embolism mortality. Pulmonary embolism (PE) carries a high mortality rate. Ten percent of untreated patients with massive PE die within the first hour. Of patients who survive the acute event, clinical recognition and early treatment are instituted in only 27%, resulting in a decreased mortality of 2.5 to 8% [17, 18] . The 73% who remain undiagnosed and untreated remain at high risk for recurrent emboli and incur a mortality of 32% from subsequent PEs (17] .
Anticoagulation-related hemorrhagic complications. In recent reviews of hemorrhagic complications of long-term oral anticoagulant therapy, the rate of major bleeding complications was shown to correlate with the intensity of anticoagulant therapy and a number of predictive risk factors including co-morbid conditions [19] [20] [21] . In the setting of hypoproteinemic nephrotic patients, possible changes of the pharmacokinetics of oral anticoagulants resulting in an increased risk of bleeding events could occur. However, there are no data in the literature studying this hypothesis. In our analysis, the baseline annual risk of major bleeding events is 3% per year, or 0.25% event per month (see Appendix for justifications).
Nine to fifteen percent of all major bleeding events were fatal in Landefeld's study [20] . A similar fatality rate of 14% was derived from a review of five studies of anticoagulant therapy alter myocardial infarction [22] . Using data from the Sixty Plus Reinfarction Study, the risk of major morbidity in survivors of a major bleed was estimated to be 5.4% [23] . Efficacy of oral anticoagulation. Although some series suggest clinical efficacy [3, 7] , there are no reports in the literature specifically examining the efficacy of oral anticoagulation in the clinical setting of nephrotic patients. We used combined trials in other clinical settings to assess the effectiveness of oral anticoagulation in preventing venous thromboembolism [24] . Efficacy was calculated as follows:
% events in untreated patients -% events in treated patients % events in untreated patients
Using the above formula, oral anticoagulation was found to be 70% effective in preventing venous thromboembolism.
Death from natural causes and from membranous nephropathy
The mortality related to patient's age, sex and race was calculated from standard tables of vital statistics by taking the reciprocal of the life expectancy [25] . The excess annual mortality rate for membranous nephropathy was obtained from data on the natural history of untreated patients [26] . The mean age for patients with membranous nephropathy was 50 years [24] .
Results
Baseline analysis Using the baseline probabilities and utilities defined in Table  1 , prophylactic oral anticoagulation was the preferred strategy. Specifically, the difference between the number of fatal pulmonary embolic episodes prevented by prophylactic administration of anticoagulants and those prevented by anticoagulants administered only after a thromboembolic event was balanced against the number of fatal hemorrhages induced by prophylactic anticoagulation. This relationship is depicted in Figure 2 for a hypothetical cohort of 10,000 fifty-year-old nephrotic patients.
The overall number of fatal emboli prevented by the prophylactic oral anticoagulant therapy exceeded the number of fatal I -- Table 2 . Frequency of venous thrombosis in adults with nephrotic syndrome Abbreviations are: N, number of patients; MGN, membranous nephropathy a Patients with nephrotic syndrome of all other types, excluding those with diabetic nephropathy bleeding events for all ranges of nephrotic syndrome duration. For the clinical scenario of a 50-year-old patient with membranous nephropathy who remained nephrotic for two years, prophylactic oral anticoagulation (Observation) yielded the greatest quality-adjusted life expectancy (15.9 QALYs). This represented an additional 2.5 months of quality-adjusted survival compared to the Observation strategy (15.7 QALYs).
Sensitivity analysis Sensitivity analysis provides a tool for addressing the uncertainty of medical problems. By varying the probabilities and utility values over a wide range, we can assess how such variations might affect the ranking of strategies. Sensitivity analyses were performed on all parameters in the model. The subsequent analyses refer to 50-year-old patients with idiopathic membranous nephropathy, and who remained nephrotic for two years. Rate of thromboembolic events. A one-way sensitivity analysis looks at the effect of varying a single variable while holding all others constant. In Figure 3 , quality-adjusted life years are shown on the vertical axis as a function of the monthly rate of venous thrombosis (DVT and RVT) on the horizontal axis. Each line represents a different strategy. As the likelihood of thromboembolic events (DVT and RVT) increases, the gain provided by prophylactic oral anticoagulant therapy increases. Each line in the graph represents the expected utility for a given strategy. The threshold probability of venous thrombosis is 0.4% per month for proximal thrombosis in the legs and 0.2% per month for renal vein thrombosis, less than half the baseline value. Only below that threshold, the Observation strategy is preferred over prophylactic Anticoagulation. Monthly rate of major bleeding events Likelihood of embolization in patients with RVT and DVT. In sensitivity analyses (results not shown) we tested the effect of varying the baseline rate of pulmonary embolism (30%) in untreated RVT. Observation became preferred over prophylactic Anticoagulation only if the likelihood of embolization was below 6%.
Risk of bleeding. Figure 4 represents a one-way sensitivity analysis of the monthly risk of bleeding. Prophylactic anticoagulant therapy (Anticoagulation) remained the preferred strategy unless the monthly risk of major bleeding events was over 0.6% per month (7% per year), considerably more than the baseline value of 0.25%.
In addition to a one-way sensitivity analysis, the effect of varying two or three parameters simultaneously could be assessed. These sensitivity analyses were called, respectively, two-way and three-way sensitivity analysis. Figure 5 is a three-way sensitivity analysis in which the horizontal axis represents the rate of pulmonary embolism given the presence of an acute DVT or RVT, while the vertical axis represents the rate of bleeding events. The two curves describe threshold regions for two different efficacy rates associated with anticoagulant therapy. In the region towards the upper left, the Observation strategy is preferred, while Anticoagulation is optimal in the region towards the lower right. For all values falling below any line, Anticoagulation is preferred. At the baseline values, Anticoagulation is preferred. As the efficacy of anticoagulant therapy decreases, the region in which Anticoagulation is preferred becomes smaller.
Although clinical data on the incidence of venous thrombosis in this population are lacking, we also extended our analysis to study the clinical scenario of patients with other varieties of nephrotic syndrome. In this clinical setting, where the incidence of thromboembolic events seemed to be lower (Table 2) , prophylactic oral anticoagulation (Anticoagulation) remained the preferred strategy, still providing a small benefit compared to the Observation strategy. However, sensitivity analyses performed on key variables (that is, risk of major bleeding events, likelihood of pulmonary embolism given acute thrombosis), affected the ranking of strategies, and the benefits provided by the administration of prophylactic anticoagulants were outweighted by the risks.
DIscussion
Literature indicates that among nephrotic patients, the incidence of thromboses is much more common among those with idiopathic membranous nephropathy compared to those with nephrotic syndrome of any other variety. In spite of this risk, oral anticoagulant therapy traditionally has been confined to patients with diagnosed acute thrombosis or in survivors of an acute pulmonary embolic event, with some authors warning that the risk of thrombosis is not sufficient to justify the risk of prophylactic oral anticoagulation. Our model suggests that prophylactic oral anticoagulation administered while patients remain nephrotic increases life expectancy, and that the benefit provided by its efficacy in preventing pulmonary embolization outweights its risks. This result extends to a wide range of nephrotic syndrome duration, and neither age, nor gender affect this benefit.
The literature is controversial about the incidence of renal vein thrombosis, deep vein thrombosis in the legs, and the likelihood of pulmonary embolism in patients with established RVT. However, we performed multiple sensitivity analyses (Figs. 3-5) on these "key" clinical parameters. Our results revealed that for observation to be preferred over prophylactic anticoagulation, the monthly rate of venous thrombosis would have to be more than two times lower than our baseline value (Fig. 3) , and the monthly rate of bleeding events would have to exceed that of our baseline analysis by a factor of two (Fig. 4) . Furthermore, for patients with established RVT, the likelihood of pulmonary embolism has to be below 6%, much less than all estimates found in the literature, for Observation to be preferred over prophylactic oral Anticoagulation.
Prophylactic anticoagulation remains the preferred strategy, although we deliberately biased our analysis against this strategy. First, the prevalence of RVT varied according to whether a clinical or a venographic diagnosis was considered (Table 2) ; the latter showed a much higher prevalence. In our analysis, we reduced the incidence of RVT to that of symptomatic RVT which widely underestimated the benefit prophylactic anticoagulation provided in also preventing embolization due to asymptomatic RVT (Appendix). Secondly, our estimated bleeding rate (3% per year) corresponded to the risk of patients with one or two risk factors for bleeding [20, 21] (Appendix) and represented an "upper range" estimate. Interpretation and evaluation of an analysis such as this involve assessment of the fidelity of the model. Does our model's structure adequately represent the complexity of the clinical problem? First, the occurrence of well-recognized thromboembolic complications other than venous thromboses including arterial thrombosis (axillary, femoral, ophtalmic, carotid), and unusual localization of venous thrombosis (mesenteric, portal, subclavian vein) [27] [28] [29] was not represented. Secondly, the occurrence of renal complications following acute renal vein thrombosis (flank pain, hematuria, deterioration in renal function) was not represented either. However, exluding these events from our model added another bias against prophylactic administration of anticoagulants which strengthened our result. Indeed, oral anticoagulation will undoubtedly provide some degree of protection against these complications, thus increasing the benefit provided by its prophylactic administration.
For nephrotic patients with other types of nephropathy (membranoproliferative and rapidly progressive glomerulonephritis, focal glomerulosclerosis), much uncertainty surrounds the incidence of thromboembolic phenomena; however, it seems undoubtedly lower. Excluding patients with diabetic nephropathy alone or in addition to other nephropathy because of the presence of multiple comorbidities, like retinopathy or hypertension which could affect the conclusions, we also studied the consequences of prophylactic oral anticoagulants in this population. In this setting, our baseline analysis shows that prophylactic oral anticoagulation still provides a small gain over observation for all ranges of nephrotic syndrome duration.
However, compared to the scenario of patients with idiopathic membranous nephropathy small variations on key parameters influence the outcome and the ranking of the strategies. In this clinical setting where thrombosis is less common compared to patients with membranous nephropathy, the number of fatal pulmonary emboli prevented by prophylactic anticoagulants is easily overwhelmed by the risk of major bleeding complications. In such clinical situations, where the gain between the two strategies is not significant and the analysis is very sensitive to many of the key parameters, the optimal therapeutic decision becomes a toss-up [30] .
Decision about choices of prophylactic anticoagulation for nephrotic patients with MGN involves consideration of many complex variables, including the risk of DVT and/or RVT, the likelihood of embolization, and the risk of bleeding. Our model handles this complexity and suggests that the extremely high rate of thromboembolic events justifies the use of prophylactic anticoagulation. However, a model like this one may not be sufficient to recommend uniformly prophylactic oral anticoagulation in nephrotic patients with MGN. Decision analysis models do not replace the need for prospective randomized clinical trials. Hence, in addition to suggesting that in the setting of nephrotic patients with MGN the benefits of oral anticoagulation outweigh the risks, the results of the present study should prompt a large multicentric prospective clinical trial to quantify more precisely the incidence of thromboembolic events and evaluate the consequences of oral anticoagulation. 
Assumptions
In formulating our model, we made a number of simplifying assumptions.
(1.) Anticoagulant therapy is administered as long as patients remain nephrotic. If remission of the nephrotic syndrome occurs, anticoagulant therapy is discontinued.
(2.) Nephrotic syndrome arising in children or in patients with diabetic nephropathy were excluded from our analysis. (5.) The short-term morbidity from a pulmonary embolism is more severe than the short-term morbidities from systemic hemorrhage or acute thrombosis (DVT or RVT). Patients who experience two of these events in the same cycle are assigned the quality adjustment for the more severe.
(6.) We did not model long-term morbidity from recurrent pulmonary embolism (such as pulmonary hypertension, right-sided heart failure).
(7.) Patients sustaining long-term morbidity from an event are still subject to the risks of future events.
Markov models
In a Markov process, patients in a hypothetical cohort are exposed to the same set of chance events repetitively over time. The passage of time is divided into intervals called cycles; in each monthly cycle, recurrent chance events (such as hemorrhage, embolism) may lead to a transition to a different state of health. The simulation ultimately calculates the average life expectancy of the cohort [6] . The Markov model is represented by a rectangular node with circles connected by an arrow (Fig. 1A) . Patient's states of health are shown as branches emanating from the Markov node.
Patients begin the Markov process in different states depending on the strategy chosen. In the Observation strategy, patients begin in the state OK off Anticoagulation, whereas in the Anticoagulation strategy, they begin in the state OK on Anticoagulation. Patients remain in the same state for ensuing cycles unless they experience one or more adverse events, represented by a cascaded set of subtrees (Fig. 1B-D) . During each cycle, patients may die of other causes, including age, sex, race, and membranous nephropathy-related excess mortality (moving to the Dead state). If they survive, they may develop Deep Venous Thrombosis and/or Renal Vein Thrombosis, which may lead to Pulmonary Embolism. Pulmonary Embolism may be fatal. Survivors of pulmonary embolism as well as patients with renal and/or deep venous thrombosis then face the complications of anticoagulant therapy. Patients receiving anticoagulant therapy immediately (Anticoagulation strategy) may also suffer from bleeding events. Bleeding may be fatal, or may lead to major (that is, long-term), or minor (that is, short-term) morbidity. Assignment of utilities In this analysis, the outcome of each strategy is measured (1) by calculating the number of fatal complications from embolic and major bleeding events for a hypothetical cohort of 10,000 nephrotic patients; and (2) in terms of quality-adjusted life years (QALYs) [31] . This scale addresses both longevity and quality of life (utility). As life expectancy is calculated by the Markov process, it is adjusted for the loss of quality experienced by the patient with each strategy. Quality of life is diminished by reduced functional capabilities in both the short-and long-term. A month spent in the patient's baseline state of health is assigned one full quality-adjusted month, and months in which the patient has morbidity (such as hemiplegia or pulmonary embolism) are given values between zero and one. Table 3 lists the baseline short-term and long-term quality-of-life adjustments used in the analysis.
Appendix B: Explanations and justification for the data used in the baseline analysis Incidence of renal vein thrombosis (RVT) in nephrotic patients Studies on RVT in nephrotic patients indicate an average prevalence of 35%. However, in individual studies this number ranges from 5% to 60% [1-3, 7-11]. Several reasons explain this wide range. First, it has been shown that thromboembolic events are more frequent in association with idiopathic membranous nephropathy [1-3, 7-11]. Thus, in studies including all types of nephrotic patients, the incidence of RVT is probably underestimated when compared to patients with membranous nephropathy, while it is overestimated compared to patients with other types of glomerular diseases.
Secondly, the intensity of hypercoagulability among nephrotic patients seems to correlate the degree of hypoalbuminemia, since thromboses are particularly frequent at plasma albumin concentrations below 2 gldl [1-3, 7-Il]. Thus, studies including heterogeneous groups of nephrotic patients with different plasma albumin concentrations may underestimate the incidence of thromboembolic events when compared to patients with low plasma albumin, and overestimate the incidence when compared to patients with normal plasma albumin levels.
Third, experience in the evaluation of patients with RVT demonstrated the presence of two different modes of clinical presentation: acute and chronic [7] . Acute RVT is characterized by flank pain, hematuria, and deterioration of renal function while chronic RVT is usually asymptomatic [7] . Thus, in studies where nephrotic patients were prospectively and systematically evaluated for the presence of RVT with intravenous pyelogram and inferior vena cavagram the incidence of RVT was high, between 1.8% and 9% per month [6, 7, 10] ( Table 2A) . On the other hand, in studies where only symptomatic patients underwent a radiologic diagnostic procedure the incidence of clinically apparent RVT was much lower, around 0.5% per month (Table 2B) [9, 11] .
We used the studies for which time-dependent data are available to calculate the monthly incidence of RVT. When data on the mean follow-up period were lacking, we used the maximum follow-up observation. However, this assumption creates an underestimation of the real incidence of RVT in nephrotic patients. In our analysis, we chose a baseline value of 0,5% per month for the incidence of RVT, corresponding to the incidence of clinically apparent RVT. By omitting silent RVT, this baseline value underestimates the real incidence of RVT and deliberately biases our model in favor of the Observation strategy.
Incidence of deep venous thrombosis (DVT) in nephrotic patients
Series studying the incidence of deep venous thrombosis in the lower limbs are shown in Table 2C . For patients with membranous nephropathy, the incidence of DVT ranges between 0.5% and 1.6% per month [9] . This represents a relative risk of at least 50, when compared to a 60-to 70-year-old hospitalized population where the incidence of deep venous thrombosis is 0.01% per month [32] . In our baseline analysis, we used a baseline value of 1% per month for the incidence of acute DVT, which is a weighted average from the two studies mentioned above. Only the occurrence of proximal (thigh) acute venous thrombosis was considered.
In the setting of nephrotic syndrome of other types, the incidence of venous thrombosis in the extremities ranges between 0.13 and 2% per month [7, 9] .
Likelihood of embolization in patients with RVT
The likelihood of pulmonary embolism in patients with RVT is difficult to assess. Specifically, whether the clinically inapparent RVT are associated with a high incidence of pulmonary emboli remains unanswered. Cameron carefully summarized the available data on the frequency of pulmonary embolism in the particular clinical setting of RVT [1] . In his review, the incidence of pulmonary embolism ranged from 10% to 60% depending on the diagnostic technique. However, since no pulmonary angiography was done in these patients, a definite interpretation of these findings is not possible.
In our baseline analysis we used an expert's estimate of the incidence of pulmonary embolization in patients with RVT: 30% of patients with untreated RVT will develop pulmonary embolism [1].
Likelihood of embolization in patients with DVT in the legs
The likelihood of pulmonary embolism is dependent upon anatomical location, and not the clinical setting in which the thrombosis occurs. Thus, 50% of untreated acute proximal venous thrombosis in the legs will embolize to the lungs [15, 16] .
Anticoagulation-related hemorrhagic complications
In reviews of major hemorrhagic complications of oral anticoagulant therapy, major bleeds included intracranial and retroperitoneal hemorrhage as well as those which resulted in hospitalization, transfusions or death [19] [20] [21] . By analyzing risk factors known at the start of therapy, Landefeld et al developed a method for estimating the risk of major bleeding in patients receiving long-term anticoagulant therapy [20, 211. Five independent risks factors [(1) age 65 or older; (2) history of stroke; (3) history of gastrointestinal bleeding; (4) serious comorbid condition including recent myocardial infarction, renal insufficiency, liver failure, or cancer, and (5) atrial fibrillation] were predictive of major bleeding events. For the high risk patient with three or more risk factors, the cumulative incidence of major bleeding was 17% per year, or 1.4% per patient-month. In comparison, middle risk patients with one or two risk factors had an annual incidence of major bleeding averaging 3% per year, or 0.25% per patient-month. In low risk patients with no risk factors, the annual incidence of major bleeding events is 0.5%, or less than 0.05% per patient-month.
In our baseline analysis, the risk of major bleeding events corresponded to the bleeding risk of patients with one or two risk factors (3% per year or 0.25% per patient-month).
